Filtered By:
Condition: Thrombosis
Drug: Clopidogrel
This page shows you your search results in order of date. This is page number 15.
Order by Relevance | Date
Total 536 results found since Jan 2013.
Current status of antithrombotic therapy and in-hospital outcomes in patients with atrial fibrillation undergoing percutaneous coronary intervention in Germany
CONCLUSION: The preferred therapy after PCI in patients with AF is DAT with a NOAC and clopidogrel. In-hospital ischemic and bleeding events were rare. The recommended durations for combination therapy vary considerably.PMID:35243515 | DOI:10.1007/s00059-022-05099-6
Source: Herz - March 4, 2022 Category: Cardiology Authors: Uwe Zeymer Ralph Toelg Harm Wienbergen Hans-Peter Hobbach Alessandro Cuneo Raffi Bekeredjian Oliver Ritter Birgit Hailer Klaus Hertting Marcus Hennersdorf Werner Scholtz Peter Lanzer Harald Mudra Markus Schwefer Peter-Lothar Schwimmbeck Christoph Liebetra Source Type: research
Antiplatelet agents for chronic kidney disease
CONCLUSIONS: Antiplatelet agents probably reduced myocardial infarction and increased major bleeding, but do not appear to reduce all-cause and cardiovascular death among people with CKD and those treated with dialysis. The treatment effects of antiplatelet agents compared with each other are uncertain.PMID:35224730 | DOI:10.1002/14651858.CD008834.pub4
Source: Cochrane Database of Systematic Reviews - February 28, 2022 Category: General Medicine Authors: Patrizia Natale Suetonia C Palmer Valeria M Saglimbene Marinella Ruospo Mona Razavian Jonathan C Craig Meg J Jardine Angela C Webster Giovanni Fm Strippoli Source Type: research
Clinical Outcomes After Percutaneous Coronary Intervention Over Time on the Basis of CYP2C19 Polymorphisms
In conclusion, these data demonstrate a higher risk for ischemic events in patients with 2 CYP2C19 LOF alleles who are prescribed clopidogrel, seen at 3 months after PCI, that is not sustained for 12 months.
Source: Journal of Cardiovascular Pharmacology - February 1, 2022 Category: Cardiology Tags: Original Article Source Type: research
FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Association of CYP2C19 Loss-of-Function Alleles with Major Adverse Cardiovascular Events of Clopidogrel in Stable Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention: Meta-analysis
ConclusionStable CAD patients treated with clopidogrel and carriedCYP2C19 LoF alleles undergoing PCI were associated with significantly increased risk of MACE compared to non-carriers, even markedly significant for Asian patients.
Source: Cardiovascular Drugs and Therapy - December 1, 2021 Category: Cardiology Source Type: research
Expert Opinion on P2Y12 Inhibitors Use in Management of Acute Coronary Syndromes: Focus on Ticagrelor
In conclusion, ticagrelor (180 mg, 90 mg, and 60 mg doses), a potent antiplatelet is expected to reshape the antiplatelet use in the management of ACS.PMID:34781659
Source: Journal of the Association of Physicians of India - November 16, 2021 Category: General Medicine Authors: Immaneni Sathyamurthy M S Hiremath Jitendra Pal Sawhney Subhash Chandra Hrudanand Mishra C K Ponde Shuvanan Ray Suhas Hardas Sunil Sathe P C Rath Bagirath R Girish B Navasundi Vilas Magarkar C N Makhale Suvro Banerjee P R Vaidyanathan Amal Kanti Sen Pande Source Type: research
